At Seres, specializes in the design and development of microbiome therapeutics for the treatment and prevention of infectious diseases. Works on preclinical and clinical programs, driving therapeutic design and microbiome readouts. As lead of SER-155, oversaw the application and award of a CARB-X contract for $5.6 mil to support development of SER-155 to prevent antibiotic resistant infections. Led the microbiome analyses for SER-109 and SER-262, providing key insights to move SER-109 to ph3. Prior, a Helen Hay Whitney fellow in the Regev lab at the Broad Institute of MIT & Harvard. Developed novel microscopy, microfluidic, and computational approaches to probe host-pathogen interactions at the single cell level. Received his PhD from the Biological Sciences in Public Health at Harvard.